A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

This clinical trial is designed to assess the safety, preliminary efficacy, and pharmacokinetics (PK) of DS3790a monotherapy and combination regimens in participants with hematological malignancies.

Trial Details

NCT ID
NCT07220616
Phase
PHASE1 / PHASE2
Sponsor
Daiichi Sankyo
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • DS3790a
  • Combination drug
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597
  • Lille, France|50.63391,3.05512
  • Pierre-Bénite, France|45.70359,4.82424
  • Villejuif, France|48.7939,2.35992
  • Bologna, Italy|44.49381,11.33875

Key Eligibility Criteria

  • To be eligible to participate in this trial, an individual must meet all the following criteria:
  • Sign and date the ICF, prior to the start of any trial-specific procedures.
  • Adults \>=18 years at the time the ICF is signed.
  • History of one of the histologically documented hematologic malignancies according to the 5th edition of WHO classification as specified in the pro…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →